Sentences with phrase «endocrine cancer»

Thyroid cancer is the most common endocrine cancer in most countries and the incidence of thyroid cancer is increasing.

Adrenocortical carcinoma (ACC) is a rare endocrine cancer with limited therapeutic options and overall poor outcome.

Also, I am aiming to establish an endocrine cancer comparative oncology consortium.

Floryne Buishand, 30, from the Netherlands, is a postdoctoral researcher at the National Cancer Institute / NIH, Bethesda, USA, studies genomic changes associated with endocrine cancers with the ultimate goal of identifying novel diagnostic and prognostic markers, as well as novel therapeutic targets.

Endocrine cancers induce such varied clinical signs that they can be challenging to diagnose.

Not exact matches

Numerous studies have shown that soy, as a phytoestrogen (mimics estrogen and binds to estrogen receptors, blocking actual estrogen from doing the same), interferes with menstruation and may disrupt the endocrine system, much in the same way some breast cancer medications do.

Most women don't understand that the incidence of endocrine disruptive disorders such as endometriosis, fibroids, polycystic ovarian syndrome, infertility, early onset puberty, early onset menopause, heavy, painful and prolonged periods and breast cancer are mainly caused by the endocrine disruptive chemicals found in skin, hair, beauty and personal products.

While there have been no proven studies to show that the chemicals used in these products are harmful, it is thought that they can be both cancer - causing and endocrine system disrupting.

It was noted that xylene and ethyl benzene were emitted by the diapers, chemicals that are suspected endocrine, neurological and respiratory toxins; along with styrene, a chemical linked to cancer and isopropylene, a neurotoxin.

Many of these chemicals have been shown to be harmful to reproductive organs, can cause Cancer, skin irritations, disrupt endocrine function, been linked to Autism and more.

Dioxin, by far the most toxic of chemicals regulated by the Environmental Protection Agency, is linked to cancer, birth defects, liver damage, skin diseases, immune system disorders and changes in endocrine regulation.

It acts as an environmental estrogen and can disrupt the function of the endocrine system, possibly leading to cancer and birth defects, some experts say.

«They usually contain formaldehyde,» he explains, «which are an endocrine disruptor that can cause many, many long term health problems, such as cancers and developmental disorders.

These flame retardants have been shown to cause serious health disorders including endocrine disruption, cancer, birth defects, hormone disruption, reproductive and neurological disorders and learning disabilities such as ADHD, mental retardation, and hyperactivity.

Again, bisphenol - A is an endocrine disruptor that has been linked to lower sperm count, early onset of puberty, breast cancer, and obesity.

Every exposure to radiation poses health risks, including programmed cell death, genetic mutations, cancers, leukemia, birth defects, and reproductive, immune and endocrine system disorders.

Therefore, common treatments such as endocrine therapy and molecular targeting of the HER - 2 receptor are not effective for this breast cancer subtype.

Women who did not receive endocrine therapy as a treatment for their breast cancer had a weaker, but still significant association.

However, other research has suggested that the estrogen - like effects of isoflavones may reduce the effectiveness of endocrine therapies used to treat breast cancer.

They say their study, published online in Endocrine Related Cancers, provides some surprising findings about HDAC inhibitors, which all seemingly do the same thing — remove the HDAC enzymes that wrap DNA so tightly that genes are silenced.

Ain attended the annual Endocrine Society meeting in Toronto, where Bryan Haugen, head of the endocrinology division at the University of Colorado School of Medicine, told Ain that several of his most popular cell lines were not actually thyroid cancer.

Among areas the panel says should be studied further are possible cancer, reproductive, neurological, and immunological effects of endocrine disruptors.

The drug was approved by the FDA as a combination first - line therapy for postmenopausal women with ER + / HER2 - breast cancer, as initial endocrine - based treatment for their metastatic disease.

«There is good reason to suspect that increasing chemical production and use is related to the growing incidence of endocrine - associated disorders over the past 20 years, including male reproductive problems, early female puberty, cancers and neurobehavioral disorders,» said Endocrine Society member Andrea C. Gore, PhD, the guide's leaendocrine - associated disorders over the past 20 years, including male reproductive problems, early female puberty, cancers and neurobehavioral disorders,» said Endocrine Society member Andrea C. Gore, PhD, the guide's leaEndocrine Society member Andrea C. Gore, PhD, the guide's lead author.

A new phase 3 study in some of the most difficult - to - treat patients, women with endocrine - resistant disease, showed that the newly approved drug, palbociclib, more than doubled the time to cancer recurrence for women with hormone - receptor (HR +) positive metastatic breast cancer.

Women diagnosed with polycystic ovary syndrome — the most common hormone disorder in women of reproductive age — face a heightened risk of developing heart disease, diabetes, mental health conditions, reproductive disorders and cancer of the lining of the uterus than healthy women, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

«Major contributing factors other than age are race and family history, whereas little is known about the impact of endocrine disruptors on prostate cancer.»

Endocrine disrupters — pollutants that unbalance hormone systems — are known to harm fish, and there is growing evidence linking them to health problems in humans, including infertility and various cancers.

Prompted by the newly minted Food Quality Protection Act, the EPA begins to review malathion's safety, focusing on its effect on fetuses and the human endocrine and nervous systems, and its potential for causing cancer.

«However, some breast cancer patients still develop metastatic ER + disease despite these common endocrine therapies, so newer treatments are very important and necessary to kill endocrine therapy - resistant cancers.»

Standard treatments for ER + breast cancer are endocrine therapies such as tamoxifen and aromatase inhibitors.

Thousands of cattle and other livestock were poisoned, about 500 farms were quarantined and people across Michigan were exposed to a chemical linked to cancer, reproduction problems and endocrine disruption.

The researchers, including scientists from The Genome Institute at Washington University School of Medicine, presented the research titled, «Patient - derived xenograft study reveals endocrine therapy resistance of ER + breast cancer caused by distinct ESR1 gene aberrations.»

Contrast - enhanced digital mammography is comparable to breast MRI in evaluating residual breast cancer after neoadjuvant endocrine therapy or chemotherapy, according to the results of a study presented by Mayo Clinic researchers today at the 2017 San Antonio Breast Cancer Sympcancer after neoadjuvant endocrine therapy or chemotherapy, according to the results of a study presented by Mayo Clinic researchers today at the 2017 San Antonio Breast Cancer SympCancer Symposium.

If the tumor is large or there's obvious evidence that the cancer is in the lymph nodes, you take them out,» said author Julie Ann Sosa, M.D., chief of endocrine surgery and leader of the endocrine neoplasia diseases group at the Duke Clinical Research Institute and the Duke Cancer Instcancer is in the lymph nodes, you take them out,» said author Julie Ann Sosa, M.D., chief of endocrine surgery and leader of the endocrine neoplasia diseases group at the Duke Clinical Research Institute and the Duke Cancer InstCancer Institute.

A new University of Colorado Cancer Center study being presented today at the Endocrine Society Annual Meeting shows that even triple negative breast cancers expressing very low levels of androgen receptor may benefit from this therapy.

Accounting for about 1 percent of all pancreatic cancers, pNET is a cancer of the endocrine cells, known clinically as the islets of Langerhans, which exist in small clusters throughout the pancreas.

PFASs are endocrine - disrupting chemicals that have been associated with cancer and developmental disorders.

In spite of endocrine therapy to suppress hormone receptor activity or hormone exposure, many patients of hormone - dependent cancers encounter de novo or acquired resistance and require more aggressive treatments.

Certain medications are designed to disrupt the endocrine system, such as birth control pills and breast and prostate cancer drugs.

The researchers found that weight is most closely linked to tumours that are «endocrine - receptor positive» - the most common type of breast cancer, affecting 75 per cent of patients.

Comprehensive Study Includes All Danish Women Diagnosed with Breast Cancer from 2000 to 2003 who were Indicated for Prosigna and Treated with Endocrine Therapy

PALLAS: Palbociclib Collaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR +) / Human Epidermal Growth Factor Receptor 2 (HER2)- Negative Early Breast Cancer

Phase III Randomized, Placebo - Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy + / - One Year of Everolimus in Patients with High - Risk, Hormone Receptor - Positive and HER2 / neu Negative Breast Cancer.

e3 Breast Cancer Study - evaluating everolimus with endocrine therapy.

PELOPS: Palbociclib and Endocrine Therapy for Lobular Breast Cancer Preoperative Study: A Randomized Phase II Study of Palbociclib with Endocrine Therapy versus Endocrine Therapy Alone for Invasive Lobular Carcinoma and Invasive Ductal Carcinoma

Her research areas included breast cancer, endocrine disruption and tissue engineering.

Staff of this Program: Amanda M. Laird, MD, FACS, Chief, Section of Endocrine Surgery H. Richard Alexander, Jr., MD, Chief Surgical Officer Rebecca Burke, MD, Palliative Care Specialist Simon M. Hanft, MD, Director, Minimally Invasive Brain Tumor Surgery and Surgical Director, Pituitary Tumor Program Salma Jabbour, MD, Radiation Oncologist Timothy Kennedy, MD, FACS, Surgical Oncologist Sung Kim, MD, Radiation Oncologist Steven K. Libutti, MD, FACS, Director, Rutgers Cancer Institute and Surgical Oncologist Usha Malhotra, MD,, Medical Oncologist Stanley Trooskin, MD, FACS, Chief of General Surgery and Endocrine Surgeon Hetal Vig, MS, CGC, Genetic Counselor Elina Dykhne, APN, Advanced Practice Nurse Aleza Rubin, APN, Advanced Practice Nurse

SEATTLE, Feb. 05, 2018 (GLOBE NEWSWIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the publication of a landmark study in which Danish researchers used the Prosigna ® Breast Cancer Assay risk of recurrence (ROR) score to accurately predict rates of 10 - year distant recurrence (DR) of cancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 andCancer Assay risk of recurrence (ROR) score to accurately predict rates of 10 - year distant recurrence (DR) of cancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 andcancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 andcancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 and 2003.

The fellowship is offered in collaboration with the department of head and neck surgery, endocrine neoplasia, diagnostic and interventional radiology, neuroradiology, pathology, medical oncology and clinical genetics cancer.